 Shares of SpringWorks Therapeutics Inc. SWTX, 2.18 were up 14.9 in premarket trading on Tuesday after the company said a late-stage clinical trial evaluating its treatment for patients with progressing desmoid tumors met its primary endpoint. A desmoid tumor is a rare disease. 